Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Colson AE, Kumar PN, Ruane PJ, Chetchotisakd P, Ratanasuwan W, Liberty A, Nahass RG, Arenas-Pinto A, Post FA, Baker DA, Cahn P, Hofmann E, Watanabe D, Lu PL, Roukens AHE, Parczewski M, Wang H, Chen K, Shihadeh F, Shaughnessy M, Dvory-Sobol H, SenGupta D, Llamoso C, Rhee M, Ogbuagu O, ISLEND-2 Study Team

Open source

DOI: 10.1016/s0140-6736(26)01442-x
Published: 2026 Aug 29
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01442-x,
  title = {Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.},
  author = {Colson AE and Kumar PN and Ruane PJ and Chetchotisakd P and Ratanasuwan W and Liberty A and Nahass RG and Arenas-Pinto A and Post FA and Baker DA and Cahn P and Hofmann E and Watanabe D and Lu PL and Roukens AHE and Parczewski M and Wang H and Chen K and Shihadeh F and Shaughnessy M and Dvory-Sobol H and SenGupta D and Llamoso C and Rhee M and Ogbuagu O and ISLEND-2 Study Team},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)01442-x},
  url = {https://doi.org/10.1016/s0140-6736(26)01442-x}
}

RIS

TY  - JOUR
TI  - Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
AU  - Colson AE
AU  - Kumar PN
AU  - Ruane PJ
AU  - Chetchotisakd P
AU  - Ratanasuwan W
AU  - Liberty A
AU  - Nahass RG
AU  - Arenas-Pinto A
AU  - Post FA
AU  - Baker DA
AU  - Cahn P
AU  - Hofmann E
AU  - Watanabe D
AU  - Lu PL
AU  - Roukens AHE
AU  - Parczewski M
AU  - Wang H
AU  - Chen K
AU  - Shihadeh F
AU  - Shaughnessy M
AU  - Dvory-Sobol H
AU  - SenGupta D
AU  - Llamoso C
AU  - Rhee M
AU  - Ogbuagu O
AU  - ISLEND-2 Study Team
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)01442-x
UR  - https://doi.org/10.1016/s0140-6736(26)01442-x
ER  -

APA

AE, C., PN, K., PJ, R., P, C., W, R., A, L., RG, N., A, A., FA, P., DA, B., P, C., E, H., D, W., PL, L., AHE, R., M, P., H, W., K, C., F, S., M, S., H, D., D, S., C, L., M, R., O, O., & Team, I. S. (2026). Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)01442-x

Source records

pubmed · retrieved 2026-09-25T21:47:02.538Z